Many companies knowingly use inefficient spray-dried formulations to quickly enter Phase 1 trials, deferring major manufacturing and volumetric challenges until later development stages. This "good enough for now" approach often necessitates a complete, costly reformulation later on.

Failing to conduct comprehensive screening for strain selection and media development at the project's start creates issues that become significantly more difficult and expensive to resolve later. Small, early-stage problems can derail downstream processing and scale-up efforts entirely.

Companies often prioritize small gains in a drug's activity (PK/PD data) during candidate selection, while ignoring manufacturability. This can lead to selecting a molecule that is extremely difficult or costly to produce, a problem that a slightly less active but more manufacturable alternative would have avoided.

A great molecule isn't enough to attract investment. Scientists must demonstrate they've considered manufacturing from day one. Designing a robust process that fits a consistent GMP facility shows investors that the project is not just a scientific curiosity but a viable path to a scalable product.

When developing a medical device, the manufacturing process for the very first prototype should be designed with scalability in mind. If the process is unsolvable at a thousand-unit scale, the product concept itself is likely unviable and needs reconsideration from the earliest stages.

To ensure a smooth transition from development to production, an operations or manufacturing SME must be part of the design process from the start. Otherwise, products are developed without manufacturability in mind, leading to expensive, reactive fixes and subjective quality control during scale-up.

Lab-scale processes often rely on tight operational windows, like precise feeding times, that are unrealistic in a manufacturing environment. Strong teams pressure-test their processes by introducing plausible delays (e.g., a +/- 8-hour window for feeds) to ensure operational robustness before tech transfer.

The primary challenge for many MedTech innovations is not the initial science but translating a lab process into a robust, scalable, and GMP-compliant manufacturing system. This requires a shift from proving a concept to ensuring consistent quality and patient safety.

A process that seems simple in a development lab is often not viable in a strict GMP manufacturing environment. To create truly manufacturable therapies, process development scientists need direct, hands-on exposure to GMP constraints and workflows to avoid significant rework and delays.